Literature DB >> 8497074

A monoclonal antibody to the CDR-3 region of CD4 inhibits soluble CD4 binding to virions of human immunodeficiency virus type 1.

J P Moore1.   

Abstract

The CDR-3 region of CD4 has been proposed to be involved in the fusion reaction between human immunodeficiency virus type 1 (HIV-1) and CD4+ cells, either at a stage involving virus binding or subsequent to virus binding. Part of the evidence for this has been the observation that monoclonal antibodies (MAbs) to CDR-3 block HIV infection potently without strongly inhibiting the binding of monomeric gp120 to CD4. Here I show that, in a system using oligomeric, virion-bound gp120, a MAb to CDR-3 resembles those to CDR-2 in that it inhibits soluble CD4 binding to virions. Consequently, ternary complexes of MAb-soluble CD4-gp120 cannot be detected with CDR-2 MAbs and are detectable only at a very low level with a CDR-3 MAb, but they clearly form when a control MAb to CD4 domain 4 is used. Although not in direct conflict with previously published data on the role of CDR-3 MAbs in the inhibition of HIV-1 infection, these experiments do not support the hypothesis that the CDR-3 region is specifically involved in virus entry at a postbinding stage.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8497074      PMCID: PMC237720          DOI: 10.1128/JVI.67.6.3656-3659.1993

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding.

Authors:  U Olshevsky; E Helseth; C Furman; J Li; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

2.  Atomic structure of a fragment of human CD4 containing two immunoglobulin-like domains.

Authors:  J H Wang; Y W Yan; T P Garrett; J H Liu; D W Rodgers; R L Garlick; G E Tarr; Y Husain; E L Reinherz; S C Harrison
Journal:  Nature       Date:  1990-11-29       Impact factor: 49.962

3.  A CD4 domain important for HIV-mediated syncytium formation lies outside the virus binding site.

Authors:  D Camerini; B Seed
Journal:  Cell       Date:  1990-03-09       Impact factor: 41.582

4.  Identification of the residues in human CD4 critical for the binding of HIV.

Authors:  J Arthos; K C Deen; M A Chaikin; J A Fornwald; G Sathe; Q J Sattentau; P R Clapham; R A Weiss; J S McDougal; C Pietropaolo
Journal:  Cell       Date:  1989-05-05       Impact factor: 41.582

5.  CD4 antigen-based antireceptor peptides inhibit infectivity of human immunodeficiency virus in vitro at multiple stages of the viral life cycle.

Authors:  P L Nara; K M Hwang; D M Rausch; J D Lifson; L E Eiden
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

Review 6.  The CD4 antigen: physiological ligand and HIV receptor.

Authors:  Q J Sattentau; R A Weiss
Journal:  Cell       Date:  1988-03-11       Impact factor: 41.582

7.  Mapping the CD4 binding site for human immunodeficiency virus by alanine-scanning mutagenesis.

Authors:  A Ashkenazi; L G Presta; S A Marsters; T R Camerato; K A Rosenthal; B M Fendly; D J Capon
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

8.  Ig CDR3-like region of the CD4 molecule is involved in HIV-induced syncytia formation but not in viral entry.

Authors:  P Corbeau; M Benkirane; R Weil; C David; S Emiliani; D Olive; C Mawas; A Serre; C Devaux
Journal:  J Immunol       Date:  1993-01-01       Impact factor: 5.422

9.  CD4-derived synthetic peptide blocks the binding of HIV-1 GP120 to CD4-bearing cells and prevents HIV-1 infection.

Authors:  O Shapira-Nahor; H Golding; L K Vujcic; S Resto-Ruiz; R L Fields; F A Robey
Journal:  Cell Immunol       Date:  1990-06       Impact factor: 4.868

10.  Structural analysis of the human immunodeficiency virus-binding domain of CD4. Epitope mapping with site-directed mutants and anti-idiotypes.

Authors:  Q J Sattentau; J Arthos; K Deen; N Hanna; D Healey; P C Beverley; R Sweet; A Truneh
Journal:  J Exp Med       Date:  1989-10-01       Impact factor: 14.307

View more
  7 in total

1.  Postbinding events mediated by human immunodeficiency virus type 1 are sensitive to modifications in the D4-transmembrane linker region of CD4.

Authors:  S Moir; J Perreault; L Poulin
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

Review 2.  Virus receptors: implications for pathogenesis and the design of antiviral agents.

Authors:  L C Norkin
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

3.  Adaptation of human immunodeficiency virus type 1 to cells expressing a binding-deficient CD4 mutant (lysine 46 to aspartic acid).

Authors:  H R Choe; J Sodroski
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

4.  Role of CD4 epitopes outside the gp120-binding site during entry of human immunodeficiency virus type 1.

Authors:  J H Simon; P Stumbles; N Signoret; C Somoza; M Puklavec; Q J Sattentau; A N Barclay; W James
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

Review 5.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

6.  Determinants of human immunodeficiency virus type 1 entry in the CDR2 loop of the CD4 glycoprotein.

Authors:  D Brand; K Srinivasan; J Sodroski
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

7.  Monoclonal antibodies to the V2 domain of MN-rgp120: fine mapping of epitopes and inhibition of α4β7 binding.

Authors:  Gerald R Nakamura; Dora P A J Fonseca; Sara M O'Rourke; Aaron L Vollrath; Phillip W Berman
Journal:  PLoS One       Date:  2012-06-13       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.